Student presentation examines autism as a potential qualifying considition for medical marijuana in Ohio
Among the many virtures of a class on marijuana law and policy, and one reason I have students do presentation on topics of their choice, is the opporutnity to look at some issue with a broad landscape approach and then at related issues with a more refined focus. During what I can hardly believe is the final week of my class, the first student presentation will be exploring medical marijuana programs around the nation. Then, in what is scheduled to be the fourth presentation, a different student will look specificaly at autism as a potential qualifying considition for medical marijuana in the Buckeye State. Here is how the topic is described by my student (along with background readings):
Medical Marijuana has been legalized in Ohio since 2016, however, Autism Spectrum Disorder (ASD) remains off of the list of qualifying conditions. ASD is a neurodevelopmental disability which effects three major domains: social interaction, communication, and behavior patterns. As of January 2022, ASD affected 1 in 44 children. House Bill 60 and House Bill 261 aim to expand what conditions qualify for the use of medical marijuana and, specifically, look to add ASD as one of those qualifying conditions.
Currently, 23 states list autism as a qualifying condition for medical marijuana use — Ohio is hopeful to be the 24th state. While there are many barriers to the recommendation of medical marijuana for autism, much of the evidence today is anecdotal. Other countries such as Turkey analyzed the relationship between medical marijuana and Autism — the study was described to be a miracle for those with Autism.
Background materials:
Lihi Bar-Lev Schleider et al., “Real life Experience of Medical Cannabis Treatment in Autism: Analysis of Safety and Efficacy” (2019)
Autisim Science Foundation, “Use of Medical Marijuana“
Peter Hess, “Cannabis and autism, explained“
Serap Bilge & Barış Ekici, “CBD-enriched cannabis for autism spectrum disorder: an experience of a single center in Turkey and reviews of the literature” (2021)